Highlights

• Allergy Therapeutics proposes cancelling its AIM admission and re-registering as a private company in the UK.

• The board cites a limited free float, poor Liquidity and the ongoing cost of maintaining the listing.

• Both major shareholders intend to back the special resolutions, which need at least 75% of votes cast.

• The company plans a matched bargain Facility and continues to explore a primary listing in Hong Kong.

After more than two decades on London's junior market, a West Sussex allergy specialist is preparing to walk away. Allergy Therapeutics (LSE:AGY), which develops allergy vaccines and immunotherapy treatments, said at 7am on 3 November 2026 that it intends to cancel the admission of its shares to trading on AIM and re-register as a private company. The board argues the listing no longer earns its keep, yet the story does not end there: the company says it will keep working towards a primary listing in Hong Kong.

What Allergy Therapeutics announced

The company is proposing special resolutions to approve the cancellation of its AIM admission and its re-registration as a private limited company. The resolutions require the support of at least 75% of the votes cast. If they pass, the last day of dealing on AIM is expected to fall around five Business days afterwards.

Both of the company's major shareholders have indicated they intend to vote in favour. Once the shares leave AIM, the company plans to offer a matched bargain facility so that holders still have a route to buy and sell.

Why the board wants out

The board pointed to a limited free float, a lack of liquidity in the shares and the recurring costs of maintaining an AIM quotation. It said the company's Market Capitalisation "does not accurately reflect the company's value", and that raising significant Equity through AIM "would be challenging in the short or medium term".

Allergy Therapeutics has been quoted in London since 2004, so the move would end more than 20 years as one of the healthcare names among AIM stocks on the UK stock market.

The financial backdrop

The exit follows a busy year on the balance sheet. In its July trading update, the company said it expected Revenue for the year to 30 June 2026 of £59.9 million, up 9% on a reported basis from £55.0 million, and reported unaudited cash of £24.2 million at the year end against £12.8 million a year earlier.

During the year, Warrant exercises by its Shareholder lenders generated £55 million, which was used to repay all Debt owed to them. A new £40 million senior secured facility from Hayfin was drawn in full, and the shareholder lenders agreed a fresh £50 million unsecured facility that was undrawn at 30 June 2026. The company has also launched its Grassmuno grass pollen immunotherapy in Germany and guided to double-digit revenue growth for the current financial year.

Hong Kong ambitions and risks for shareholders

The Hong Kong plan is not new. In November 2025 the company said it would evaluate a dual listing on the Hong Kong Stock Exchange, and in July it said it continued to explore a potential dual primary listing there. The company now says it will continue to explore a primary listing in Hong Kong "in due course", regardless of the outcome of the vote. No timetable or terms have been set out.

For minority holders, the change is significant. A matched bargain facility relies on pairing individual buyers and sellers rather than continuous trading on an exchange, and a private company is no longer bound by the AIM Rules on disclosure. Shareholders will also need to weigh the support already signalled by the two major holders when the resolutions come to a vote.

What investors may watch next

The next milestones are the shareholder circular and meeting date, the confirmed timetable for the final day of dealing, and details of how the matched bargain facility will operate. Any formal step towards a Hong Kong listing would mark the next chapter for a company whose UK shares are set to disappear from the London Stock Exchange screens.